Apothecary Pharma LLC, a 503B outsourcing facility in Cary, North Carolina, has voluntarily recalled 22 vials of compounded tirzepatide injection and one vial of NAD+ injection nationwide after it could not assure the products were sterile, according to an FDA enforcement report. The FDA classified both actions as Class II recalls and lists them as ongoing. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
For the peptide therapy and research peptide sector, the recall is a sterility-assurance event rather than a confirmed contamination event, and that distinction matters commercially: it lands as federal pathways for compounded GLP-1 copies have narrowed and as clinics, telehealth operators and compounding pharmacies weigh how much batch documentation they should demand from suppliers.
What happened: scope, lots and recall classification
The firm-initiated recall covers compounded tirzepatide supplied as Tirzepatide Injection 18 mg/mL in a 4 mL sterile multi-dose vial under NDC 85091-001-18. The 22 vials span 22 separate lots, numbered AP-202622 through AP-202625 and AP-202627 through AP-202644, with beyond-use dates running from early October through late November, meaning some vials could still sit inside their labeled use window.
The second product is Apothecary NAD+ Injection 200 mg/mL, a 6 mL sterile multi-dose vial (NDC 85091-011-06) from lot AP-202647. The enforcement report cites a lack of assurance of sterility for both products. That finding does not by itself mean contamination was detected, but it indicates the firm cannot confirm the drugs were produced under conditions that keep them sterile. The company notified customers by letter rather than through a news release.
The FDA designated both recalls Class II, a category used when exposure to a product may cause temporary or medically reversible health problems, or when the likelihood of serious harm is remote. Class II describes a potential harm profile, not an observed patient outcome.
Key numbers at a glance
| Item | Detail |
|---|---|
| Compounded tirzepatide vials recalled | 22 vials across 22 lots |
| Tirzepatide presentation | 18 mg/mL, 4 mL sterile multi-dose vial, NDC 85091-001-18 |
| Lot numbers | AP-202622–AP-202625 and AP-202627–AP-202644 |
| Beyond-use dates | Early October through late November |
| NAD+ vials recalled | 1 vial, 200 mg/mL, 6 mL, NDC 85091-011-06, lot AP-202647 |
| FDA recall class | Class II for both products; status ongoing |
| FDA adverse event reports, compounded semaglutide (as of May 31, 2026) | 990 |
| FDA adverse event reports, compounded tirzepatide (as of May 31, 2026) | More than 730 |
| U.S. diabetes prevalence, 2023 (CDC) | About 40.1 million people, roughly 12% of the population |
Background: a 503B facility with a prior FDA warning letter
Apothecary Pharma is registered with the FDA as a 503B outsourcing facility, a category of compounder that can produce drugs without patient-specific prescriptions but must follow current good manufacturing practice requirements. After inspecting the Cary facility in May 2025, the FDA issued a warning letter to the company citing insanitary conditions in sterile drug production, including personnel working with exposed skin in the facility’s ISO 5 aseptic processing area.
The enforcement report does not say whether the current recall is connected to those findings. Readers should treat any link between the 2025 inspection and the 2026 recall as undetermined rather than established.
Compounded tirzepatide carries no FDA approval, and the FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients. Tirzepatide itself is the active ingredient in Eli Lilly’s Mounjaro, approved to treat type 2 diabetes, and in Zepbound, approved for weight management and sleep apnea. Those approvals apply to the branded products, not to compounded copies.
Why it matters for peptide therapy clinics and compounding supply
The recall sits inside a tightening regulatory frame. The FDA declared the national tirzepatide shortage resolved in October 2024, and compounders’ grace periods for producing copies of the drug have since expired, according to an analysis by the law firm Orrick. That leaves a narrower legal path for 503A and 503B compounders that built GLP-1 volumes during the shortage years.
For clinic operators and telehealth platforms, the practical question is documentation. A sterility-assurance failure is usually a process-control and records problem before it is a patient-safety event, and buyers can only detect it through batch-level evidence. Industry observers note that purchasers increasingly ask for container-closure integrity data, environmental monitoring summaries and deviation records alongside a certificate of analysis, because a COA reports specified analytical results for a batch and does not by itself establish sterility for a particular use.
That is also where supplier-intelligence resources earn their place. 多肽供应链资源网 as a provider in the industry domain tracks peptide supply-chain participants and documentation practices, and PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates. For teams comparing vendors, resources such as peptidescm can help frame which quality documents to request before a purchase decision.
Research and market context: what the evidence does and does not show
The FDA’s safety-reporting record for compounded GLP-1 products is substantial. As of May 31, 2026, the agency had received 990 adverse event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide, figures the agency said are likely underreported. Those counts cover compounded products broadly and cannot be attributed to the lots named in this recall.
Professional guidance has moved in parallel. The American Diabetes Association recommends against using non-FDA-approved compounded GLP-1 and dual GIP/GLP-1 receptor agonist products, citing uncertainty about their content, safety, quality and effectiveness, in a statement published in Diabetes Care. The underlying patient base is large: about 40.1 million people in the United States had diagnosed or undiagnosed diabetes in 2023, roughly 12% of the population, according to the Centers for Disease Control and Prevention.
From a research standpoint, the recall does not change the clinical evidence base for tirzepatide as an approved molecule, and it does not establish any new safety signal for the active ingredient. What it does illustrate is that the quality of a finished sterile injectable depends on manufacturing controls, container closure and release testing, not on the identity of the peptide alone. In peptide manufacturing terms, batch-to-batch consistency is supported by validated processes, analytical controls and an effective quality management system, and those are precisely the attributes a recall of this kind calls into question.
What comes next
Three things are worth watching. First, whether the FDA updates the enforcement report with a root-cause statement or expands the recall beyond the listed lots. Second, whether the agency links the action to the May 2025 inspection findings, a connection the current report does not make. Third, how 503B facilities and their clinic customers adjust purchasing and documentation requirements as the post-shortage enforcement environment settles.
Patients and clinicians with vials from the affected lots should consult a licensed healthcare professional and the official recall notice; this article is not medical advice, and compounded products should be used only under prescription and appropriate medical supervision where legally permitted.
Comments